Aakaar Medical Technologies Ltd (AAKAAR) — shareholding pattern, promoter holding, financials and share price
About Aakaar Medical Technologies Ltd (AAKAAR)
Aakaar Medical Technologies Ltd operates in the Medical Equipment & Supplies industry, within the Healthcare sector. It trades on the NSE as AAKAAR and on the BSE under scrip code 94576. Its ISIN is INE1GYP01013.
Incorporated in June 2013, Aakaar Medical Technologies Limited is an aesthetic medical company that offers a diverse selection of specialized cosmetic products and devices. [1]
Aakaar Medical Technologies Ltd. specializes in manufacturing and distributing medical aesthetic products and devices, targeting dermatologists, plastic surgeons, and other aesthetic practitioners.
The company launched its IPO in June 2025, raising INR 27 crores, which it is using to strengthen its working capital and expand its reach within the medical aesthetic industry.
Listed peers in Medical Equipment & Supplies: Choksi Asia Ltd, Royal Sense Ltd, Shree Pacetronix Ltd, KMS Medisurgi Ltd, Amkay Products Ltd, GKB Ophthalmics Ltd.
Valuation & Returns
10 Jul 2026At ₹64.4 a share on 10 Jul 2026, Aakaar Medical Technologies Ltd (AAKAAR) was valued at a price-to-earnings ratio of 13.76x against an industry P/E of 44.11x and a price-to-book of 1.67x on a book value of ₹38.49 per share. Solomo computes return on equity of 12.17% and return on capital employed of 15.03% from filed results.
- P/E
- 13.76x
- Industry P/E
- 44.11x
- P/B
- 1.67x
- EPS (TTM)
- ₹4.68
- Book value / share
- ₹38.49
- ROE
- 12.17%
- ROCE
- 15.03%
- ROA
- 8.36%
- Debt / equity
- 0.34x
- Dividend yield
- 0%
- EBITDA margin
- 16.61%
- 52-week range
- ₹46 – ₹105
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Aakaar Medical Technologies Ltd (AAKAAR) reported revenue of ₹66.96 crore, net profit of ₹6.64 crore and earnings per share of ₹4.69. That compares with revenue of ₹61.58 crore and net profit of ₹6.03 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹41.64 crore and net profit ₹7.42 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 19.47 | 32.78 | 46.11 | 61.58 | 66.96 |
| Net profit (₹ cr) | 1.62 | 2.15 | 2.87 | 6.03 | 6.64 |
| EPS (₹) | 23.14 | 30.71 | 41 | 5.79 | 4.69 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 40.03% | 26.88% | 8.74% |
| Profit growth | 64.90% | 45.54% | 10.12% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 67.05% of Aakaar Medical Technologies Ltd (AAKAAR). Market capitalisation was ₹91 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2025.
Largest disclosed public shareholders in Mar 2026: INDIA EQUITY FUND 1 4.97%, RAHUL B SAWAKHANDE 4.1%, AARTH AIF GROWTH FUND 3.61%, CHAITANYA GADIA 1.2%, GROBIZ SME OPPORTUNITY FUND 1.1%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 67.05% | - | - | - | - |
| Sep 2025 | 67.01% | - | - | - | - |